NovoCure (NVCR) Total Non-Current Liabilities (2014 - 2026)

NovoCure has disclosed Total Non-Current Liabilities across 13 years of filings, most recently posting $239.6 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $239.6 million, up 66.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $239.6 million (up 66.94% YoY), and the FY2025 annual result was $240.6 million, up 93.73% from the prior year.
• Total Non-Current Liabilities came in at $239.6 million for Q1 2026 at NovoCure, roughly flat from $240.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $681.2 million in Q2 2024 to a low of $124.2 million in Q4 2024.
• The 5-year median for Total Non-Current Liabilities is $586.5 million (2022), against an average of $428.6 million.
• Across the five-year window, Total Non-Current Liabilities plunged 79.45% in 2024 and surged 93.73% in 2025, its largest moves.
• NovoCure's Total Non-Current Liabilities stood at $591.7 million in 2022, then rose by 2.17% to $604.5 million in 2023, then slumped by 79.45% to $124.2 million in 2024, then surged by 93.73% to $240.6 million in 2025, then decreased by 0.42% to $239.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $239.6 million (Q1 2026), $240.6 million (Q4 2025), and $243.9 million (Q3 2025), per Business Quant data.